
## David Wright

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9479434/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	When to give aspirin to prevent preeclampsia: application of Bayesian decision theory. American Journal of Obstetrics and Gynecology, 2022, 226, S1120-S1125.	0.7	8
2	The competing risk approach for prediction of preeclampsia. American Journal of Obstetrics and Gynecology, 2020, 223, 12-23.e7.	0.7	143
3	Noninvasive Fetal Genotyping by Droplet Digital PCR to Identify Maternally Inherited Monogenic Diabetes Variants. Clinical Chemistry, 2020, 66, 958-965.	1.5	32
4	Mini-combined test compared with NICE guidelines for early risk-assessment for pre-eclampsia: the SPREE diagnostic accuracy study. Efficacy and Mechanism Evaluation, 2020, 7, 1-156.	0.9	5
5	Two-stage screening for preterm preeclampsia at 11–13 weeks' gestation. American Journal of Obstetrics and Gynecology, 2019, 220, 197.e1-197.e11.	0.7	37
6	Predictive performance of the competing risk model in screening for preeclampsia. American Journal of Obstetrics and Gynecology, 2019, 220, 199.e1-199.e13.	0.7	136
7	Aspirin delays the development of preeclampsia. American Journal of Obstetrics and Gynecology, 2019, 220, 580.e1-580.e6.	0.7	59
8	Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin on length of stay in the neonatal intensive care unit. American Journal of Obstetrics and Gynecology, 2018, 218, 612.e1-612.e6.	0.7	84
9	Aspirin for Evidence-Based Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia. American Journal of Obstetrics and Gynecology, 2017, 217, 685.e1-685.e5.	0.7	100
10	Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. New England Journal of Medicine, 2017, 377, 613-622.	13.9	1,462
11	Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation. American Journal of Obstetrics and Gynecology, 2016, 214, 103.e1-103.e12.	0.7	365
12	Competing risks model in screening for preeclampsia by maternal characteristics and medical history. American Journal of Obstetrics and Gynecology, 2015, 213, 62.e1-62.e10.	0.7	280
13	Competing Risks Model in Early Screening for Preeclampsia by Biophysical and Biochemical Markers. Fetal Diagnosis and Therapy, 2013, 33, 8-15.	0.6	464
14	A Competing Risks Model in Early Screening for Preeclampsia. Fetal Diagnosis and Therapy, 2012, 32, 171-178.	0.6	182
15	Prediction of Small-for-Gestation Neonates from Biophysical and Biochemical Markers at 11–13 Weeks. Fetal Diagnosis and Therapy, 2011, 29, 148-154.	0.6	153
16	Screening for trisomies in dichorionic twins by measurement of fetal nuchal translucency thickness according to the mixture model. Prenatal Diagnosis, 2011, 31, 16-21.	1.1	24
17	First-Trimester Screening for Trisomy 21 with Adjustment for Biochemical Results of Previous Pregnancies. Fetal Diagnosis and Therapy, 2011, 30, 194-202.	0.6	8
18	On shape detection in noisy images with particular reference to ultrasonography. Statistics and Computing, 1998, 8, 377-389.	0.8	1